Alpha 2.0
Login Register
» Authors » Bo Magnusson

Bo Magnusson

Explore the profile of Bo Magnusson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 658
Followers 0
Related Specialties
Rheumatology
Urology
General Medicine
Top 10 Co-Authors
Nicolino Ruperto
Angelo Ravelli
Angela Pistorio
Alberto Martini
Tamas Constantin
Seza Ozen
Ricardo Russo
Rolando Cimaz
Frank Dressler
Nico Wulffraat
Published In
Urology
Ann Rheum Dis
Pediatr Rheumatol Online J
N Engl J Med
Vaccine
Affiliations
Soon will be listed here.
Recent Articles
1.
ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy
Elsea S, Solyom A, Martin K, Harmatz P, Mitchell J, Lampe C, et al.
Hum Mutat . 2020 May; 41(9):1469-1487. PMID: 32449975
Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy are a spectrum of rare lysosomal storage disorders characterized by acid ceramidase deficiency (ACD), resulting from pathogenic variants in N-acylsphingosine...
2.
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients
Giancane G, Lavarello C, Pistorio A, Oliveira S, Zulian F, Cuttica R, et al.
Pediatr Rheumatol Online J . 2019 May; 17(1):24. PMID: 31118099
Background: Prednisone (PDN) in juvenile dermatomyositis (JDM), alone or in association with other immunosuppressive drugs, namely methotrexate (MTX) and cyclosporine (CSA), represents the first-line treatment option for new onset JDM...
3.
The European network for care of children with paediatric rheumatic diseases: care across borders
Dolezalova P, Anton J, Avcin T, Beresford M, Brogan P, Constantin T, et al.
Rheumatology (Oxford) . 2019 Jan; 58(7):1188-1195. PMID: 30668879
Objectives: To provide an overview of the paediatric rheumatology (PR) services in Europe, describe current delivery of care and training, set standards for care, identify unmet needs and inform future...
4.
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries
Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva E, et al.
Arthritis Res Ther . 2018 Dec; 20(1):285. PMID: 30587248
Background: The availability of methotrexate and the introduction of multiple biological agents have revolutionized the treatment of juvenile idiopathic arthritis (JIA). Several international and national drug registries have been implemented...
5.
A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities
Beukelman T, Anink J, Berntson L, Duffy C, Ellis J, Glerup M, et al.
Pediatr Rheumatol Online J . 2017 Apr; 15(1):31. PMID: 28424093
Background: To characterize the existing national and multi-national registries and cohort studies in juvenile idiopathic arthritis (JIA) and identify differences as well as areas of potential future collaboration. Methods: We...
6.
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology...
Rider L, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman B, et al.
Ann Rheum Dis . 2017 Apr; 76(5):782-791. PMID: 28385804
To develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group...
7.
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology...
Rider L, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman B, et al.
Arthritis Rheumatol . 2017 Apr; 69(5):911-923. PMID: 28382778
Objective: To develop response criteria for juvenile dermatomyositis (DM). Methods: We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical...
8.
Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy
Dworski S, Lu P, Khan A, Maranda B, Mitchell J, Parini R, et al.
Biochim Biophys Acta Mol Basis Dis . 2016 Dec; 1863(2):386-394. PMID: 27915031
Acid Ceramidase Deficiency (Farber disease, FD) is an ultra-rare Lysosomal Storage Disorder that is poorly understood and often misdiagnosed as Juvenile Idiopathic Arthritis (JIA). Hallmarks of FD are accumulation of...
9.
Consensus-based recommendations for the management of juvenile dermatomyositis
Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman B, et al.
Ann Rheum Dis . 2016 Aug; 76(2):329-340. PMID: 27515057
Background: In 2012, a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe...
10.
Diverse effects on vaccine-specific serum IgG titres and memory B cells upon methotrexate and anti-TNF-α therapy in children with rheumatic diseases: A cross-sectional study
Ingelman-Sundberg H, Laestadius A, Chrapkowska C, Mordrup K, Magnusson B, Sundberg E, et al.
Vaccine . 2016 Feb; 34(10):1304-11. PMID: 26827664
Objectives: We aimed at a comprehensive evaluation of how anti-TNF-α therapy and methotrexate treatment interferes with B cell memory in children with Paediatric Rheumatic Disease (PRD), by evaluating existing B...